{"id":"trimebutine","rwe":[{"pmid":"41901580","year":"2026","title":"Patient-Reported Epigastric Symptom Dynamics During Trimebutine Maleate Treatment: A Post-Marketing Study.","finding":"","journal":"Medicina (Kaunas, Lithuania)","studyType":"Clinical Study"},{"pmid":"41866875","year":"2025","title":"Expert Opinion on the Efficacy and Safety of Antispasmodics with a Focus on Irritable Bowel Syndrome.","finding":"","journal":"The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology","studyType":"Clinical Study"},{"pmid":"40672632","year":"2025","title":"Combination therapy with otilonium bromide and trimebutine maleate demonstrates significant clinical advantages in irritable bowel syndrome patients.","finding":"","journal":"American journal of translational research","studyType":"Clinical Study"},{"pmid":"40665404","year":"2025","title":"Massive peritoneal effusion following hip arthroscopy: a case report and review of the literature.","finding":"","journal":"Journal of medical case reports","studyType":"Clinical Study"},{"pmid":"40607383","year":"2025","title":"ER stress genes (COL1A1, LOXL2, VWF) predicts IKK-16 as a Candidate therapeutic target for colitis-related inflammation and fibrosis suppression.","finding":"","journal":"Frontiers in immunology","studyType":"Clinical Study"}],"tags":[{"label":"trimebutine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A03AA05","category":"atc"},{"label":"Active","category":"status"},{"label":"Gastrointestinal Agents","category":"pharmacology"},{"label":"Parasympatholytics","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"phase_3","safety":{"safetySignals":[{"llr":109.012,"date":"","count":89,"signal":"Hyponatraemia","source":"DrugCentral FAERS","actionTaken":"Reported 89 times (LLR=109)"},{"llr":94.402,"date":"","count":20,"signal":"Necrosis ischaemic","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=94)"},{"llr":88.106,"date":"","count":63,"signal":"Coma","source":"DrugCentral FAERS","actionTaken":"Reported 63 times (LLR=88)"},{"llr":84.068,"date":"","count":130,"signal":"Acute kidney injury","source":"DrugCentral FAERS","actionTaken":"Reported 130 times (LLR=84)"},{"llr":78.465,"date":"","count":20,"signal":"Beta haemolytic streptococcal infection","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=78)"},{"llr":73.598,"date":"","count":20,"signal":"Pneumonia streptococcal","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=74)"},{"llr":60.033,"date":"","count":45,"signal":"Colitis","source":"DrugCentral FAERS","actionTaken":"Reported 45 times (LLR=60)"},{"llr":48.536,"date":"","count":20,"signal":"Colitis microscopic","source":"DrugCentral FAERS","actionTaken":"Reported 20 times (LLR=49)"},{"llr":48.514,"date":"","count":23,"signal":"Poisoning deliberate","source":"DrugCentral FAERS","actionTaken":"Reported 23 times (LLR=49)"},{"llr":48.1,"date":"","count":34,"signal":"Rash maculo-papular","source":"DrugCentral FAERS","actionTaken":"Reported 34 times (LLR=48)"},{"llr":47.748,"date":"","count":22,"signal":"Febrile bone marrow aplasia","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=48)"},{"llr":46.787,"date":"","count":35,"signal":"Drug reaction with eosinophilia and systemic symptoms","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=47)"},{"llr":46.219,"date":"","count":19,"signal":"Anal fissure","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=46)"},{"llr":44.555,"date":"","count":45,"signal":"Interstitial lung disease","source":"DrugCentral FAERS","actionTaken":"Reported 45 times (LLR=45)"},{"llr":41.843,"date":"","count":34,"signal":"Encephalopathy","source":"DrugCentral FAERS","actionTaken":"Reported 34 times (LLR=42)"}],"commonSideEffects":[{"effect":"Hyponatraemia","drugRate":"LLR 109","severity":"common"},{"effect":"Necrosis ischaemic","drugRate":"LLR 94","severity":"common"},{"effect":"Coma","drugRate":"LLR 88","severity":"common"},{"effect":"Acute kidney injury","drugRate":"LLR 84","severity":"common"},{"effect":"Beta haemolytic streptococcal infection","drugRate":"LLR 78","severity":"common"},{"effect":"Pneumonia streptococcal","drugRate":"LLR 74","severity":"common"},{"effect":"Colitis","drugRate":"LLR 60","severity":"common"},{"effect":"Poisoning deliberate","drugRate":"LLR 49","severity":"common"},{"effect":"Rash maculo-papular","drugRate":"LLR 48","severity":"common"},{"effect":"Febrile bone marrow aplasia","drugRate":"LLR 48","severity":"common"},{"effect":"Drug reaction with eosinophilia and systemic symptoms","drugRate":"LLR 47","severity":"common"},{"effect":"Anal fissure","drugRate":"LLR 46","severity":"common"},{"effect":"Interstitial lung disease","drugRate":"LLR 45","severity":"common"},{"effect":"Encephalopathy","drugRate":"LLR 42","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"(+/-)-trimebutine","offLabel":[],"synonyms":["trimebutine maleate","trimebutine","(+/-)-Trimebutine"],"timeline":[],"approvals":[],"brandName":"(+/-)-Trimebutine","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"trimebutine","explanation":"Imagine your gut is like a muscle that can get crampy and inflamed. Trimebutine helps by blocking the signals that tell the muscle to contract and get inflamed, which can help with symptoms like cramps and diarrhea.","oneSentence":"Trimebutine works by blocking certain receptors in the gut to reduce spasms and inflammation.","technicalDetail":"Trimebutine is a muscarinic receptor antagonist and a kappa opioid receptor antagonist, which suggests it may work by blocking the action of acetylcholine and other neurotransmitters that stimulate gut contractions and inflammation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2748","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TRIMEBUTINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TRIMEBUTINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T16:03:13.442676","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T10:51:00.321832+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"oxyphencyclimine","drugSlug":"oxyphencyclimine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"dicycloverine","drugSlug":"dicycloverine","fdaApproval":"1950-05-11","relationship":"same-class"}],"genericName":"trimebutine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"oxyphencyclimine","brandName":"oxyphencyclimine","genericName":"oxyphencyclimine","approvalYear":"","relationship":"same-class"},{"drugId":"dicycloverine","brandName":"dicycloverine","genericName":"dicycloverine","approvalYear":"1950","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07421011","phase":"PHASE1","title":"Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.","status":"RECRUITING","sponsor":"Valenta Pharm JSC","startDate":"2025-11-06","conditions":["Irritable Bowel Syndrome","Gallstone Disease","GERD","Biliary Dyskinesia","Postcholecystectomy Syndrome"],"enrollment":36,"completionDate":"2026-12-31"},{"nctId":"NCT06842966","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia","status":"RECRUITING","sponsor":"Valenta Pharm JSC","startDate":"2024-10-17","conditions":["Chronic Cholecystitis","Biliary Dyskinesia"],"enrollment":300,"completionDate":"2026-12-31"},{"nctId":"NCT06676514","phase":"NA","title":"Study to Evaluate the Treatment Benefits of Probiotic Clostridium Butyricum CBM588® for IBS-D","status":"COMPLETED","sponsor":"Liaquat University of Medical & Health Sciences","startDate":"2024-11-10","conditions":["IBS-D (Diarrhea-predominant)"],"enrollment":405,"completionDate":"2025-03-10"},{"nctId":"NCT06268964","phase":"PHASE1,PHASE2","title":"Exploring Treatments for Children's Abdominal Pain: Comparing Trimebutine and Probiotics","status":"RECRUITING","sponsor":"Universidad de Colima","startDate":"2024-09-01","conditions":["Functional Abdominal Pain Syndrome","Functional Gastrointestinal Disorders","Irritable Bowel Syndrome Variant of Childhood"],"enrollment":82,"completionDate":"2025-06-30"},{"nctId":"NCT06342804","phase":"PHASE1","title":"Food Effect on the Bioavailability of 4-MUST, Tablets, 128 mg","status":"UNKNOWN","sponsor":"Valenta Pharm JSC","startDate":"2024-03-19","conditions":["Cholecystitis"],"enrollment":24,"completionDate":"2024-12-31"},{"nctId":"NCT06315387","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of 4-MUST, Tablets, 128 mg (Valenta Pharm JSC) During Single and Multiple Oral Administration in Healthy Volunteers","status":"UNKNOWN","sponsor":"Valenta Pharm JSC","startDate":"2023-12-04","conditions":["Cholecystitis"],"enrollment":42,"completionDate":"2024-12-31"},{"nctId":"NCT02986685","phase":"PHASE4","title":"Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole","status":"WITHDRAWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2016-11","conditions":["Refractory Reflux Esophagitis"],"enrollment":0,"completionDate":"2017-11"},{"nctId":"NCT04403087","phase":"PHASE4","title":"Trimebutine on the Development of Adverse Events Related to the Helicobacter Pylori Eradication Medications","status":"COMPLETED","sponsor":"Chuncheon Sacred Heart Hospital","startDate":"2021-05-01","conditions":["Helicobacter Pylori Infection"],"enrollment":132,"completionDate":"2021-07-01"},{"nctId":"NCT05379036","phase":"PHASE4","title":"Intestinal Permeability and Intestinal Microbiota in Irritable Bowel Syndrome","status":"UNKNOWN","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2021-06-23","conditions":["Irritable Bowel Syndrome With Diarrhea"],"enrollment":60,"completionDate":"2022-05-31"},{"nctId":"NCT01926444","phase":"PHASE2","title":"A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy","status":"COMPLETED","sponsor":"gicare Pharma Inc.","startDate":"2013-07","conditions":["Pain","Cancer","Colonic Diseases"],"enrollment":308,"completionDate":"2014-03"},{"nctId":"NCT03359499","phase":"PHASE2,PHASE3","title":"Impact of Bacillus Clausii Administration on Irritable Bowel Syndrome Patients","status":"COMPLETED","sponsor":"Hospital Britanico","startDate":"2017-08-12","conditions":["Irritable Bowel Syndrome"],"enrollment":80,"completionDate":"2017-11-23"},{"nctId":"NCT03036111","phase":"NA","title":"Effect of Topical Trimebutine on Pain After Hemorrhoidectomy","status":"SUSPENDED","sponsor":"Mansoura University","startDate":"2017-02-01","conditions":["Hemorrhoids"],"enrollment":42,"completionDate":"2018-04-01"},{"nctId":"NCT02276768","phase":"PHASE1","title":"Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat Method","status":"COMPLETED","sponsor":"gicare Pharma Inc.","startDate":"2014-10","conditions":["Pain","Cancer","Colonic Disease"],"enrollment":90,"completionDate":"2014-12"},{"nctId":"NCT01507922","phase":"PHASE4","title":"Comparative Efficacy and Safety of Fenoverine","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2011-12","conditions":["Irritable Bowel Syndrome"],"enrollment":186,"completionDate":"2013-06"},{"nctId":"NCT01984931","phase":"PHASE3","title":"Study of Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)for Treatment of Post Operative Nausea and Vomiting","status":"UNKNOWN","sponsor":"CM Chungmu Hospital","startDate":"2013-10","conditions":["Nausea","Vomiting"],"enrollment":45,"completionDate":"2013-12"},{"nctId":"NCT01738425","phase":"PHASE1","title":"A Clinical Phase I Study on GIC-1001 in Healthy Volunteers","status":"COMPLETED","sponsor":"gicare Pharma Inc.","startDate":"2012-11","conditions":["Colonic Diseases"],"enrollment":80,"completionDate":"2013-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"003502","UNII":"QZ1OJ92E5R","CHEBI":"CHEBI:32261","INN_ID":"2773","RXNORM":"10819","UMLSCUI":"C0041023","ChEMBL_ID":"CHEMBL190044","KEGG_DRUG":"D01500","DRUGBANK_ID":"DB09089","PUBCHEM_CID":"5573","SNOMEDCT_US":"698184001","SECONDARY_CAS_RN":"34140-59-5","MESH_DESCRIPTOR_UI":"D014287"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":263,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"A03AA05","allCodes":["A03AA05"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 7","pmid":"41901580","title":"Patient-Reported Epigastric Symptom Dynamics During Trimebutine Maleate Treatment: A Post-Marketing Study.","journal":"Medicina (Kaunas, Lithuania)"},{"date":"2025 Nov 25","pmid":"41866875","title":"Expert Opinion on the Efficacy and Safety of Antispasmodics with a Focus on Irritable Bowel Syndrome.","journal":"The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology"},{"date":"2025","pmid":"40672632","title":"Combination therapy with otilonium bromide and trimebutine maleate demonstrates significant clinical advantages in irritable bowel syndrome patients.","journal":"American journal of translational research"},{"date":"2025 Jul 15","pmid":"40665404","title":"Massive peritoneal effusion following hip arthroscopy: a case report and review of the literature.","journal":"Journal of medical case reports"},{"date":"2025","pmid":"40607383","title":"ER stress genes (COL1A1, LOXL2, VWF) predicts IKK-16 as a Candidate therapeutic target for colitis-related inflammation and fibrosis suppression.","journal":"Frontiers in immunology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"(+/-)-Trimebutine is a small molecule with the synonyms TRIMEBUTINA, TRIMEBUTINE, TRIMEBUTINE, and TRIMEBUTINE.","enrichmentLevel":5,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T10:51:00.321832+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}